Votrient (Ovarian Cancer) Analysis and Forecasts to 2020


#28294

32pages

GlobalData

$ 2000

In Stock

 

GlobalDatas pharmaceuticals report, Votrient (Ovarian Cancer) - Analysis and Forecasts to 2020 provides Votrient sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Ovarian Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

 

Scope

 

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Votrient including sales data 
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Votrient including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecasts for 2013-2020 for Votrient in the seven major markets

 

Reasons to buy

 

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Contents

 

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3


2 Introduction 4
2.1 Ovarian Cancer 4
2.2 Ovarian Cancer Market 4
2.3 Epidemiology 4
2.4 Etiology 6
2.4.1 Age 6
2.4.2 Inherited Gene Mutations 6
2.4.3 A Previous Cancer Diagnosis 6
2.4.4 Early Menstruation or Late menopause 7
2.4.5 Family History of Ovarian Cancer 7
2.5 GlobalData Report Guidance 7


3 Ovarian Cancer: Market Characterization 8
3.1 Ovarian Cancer Market 8
3.2 Ovarian Cancer Market Forecasts and CAGR 8
3.3 Drivers for Ovarian Cancer Market 9
3.3.1 High Incidence 9
3.3.2 High Mortality Rate 10
3.3.3 Increased Use of Chemotherapy in Ovarian Cancer 11
3.3.4 Emergence of Targeted Drugs 11
3.3.5 Recurrence of Tumor 11
3.3.6 Low Initial Diagnosis Rate 11


4 Tumor-Node-Metastases (TNM) Classification of Ovarian Cancer 12


5 Votrient (pazopanib) 15
5.1 Introduction 15
5.2 Mechanism of Action 15
5.3 Clinical Studies 15
5.4 Approval History of Votrient 15
5.5 Factors Affecting Sales of Votrient 16
5.5.1 Unmet Medical Need 16
5.5.2 Treatment Mechanism 16
5.5.3 Limited Competition 16
5.6 Drug Evaluation 16
5.6.1 Drug Risk Benefit Score 16
5.6.2 Intensity of Competition 17
5.7 Sales Forecasts 17
5.7.1 Target Patient Pool of Votrient 17
5.7.2 Dosing 18
5.7.3 Market Penetration 18
5.7.4 Annual Cost of Therapy 18
5.7.5 Sales Projections of Votrient 19


6 Ovarian Cancer Market: Appendix 28
6.1 Market Definitions 28
6.2 List of Abberiviations 28
6.3 Research Methodology 28
6.3.1 Coverage 28
6.3.2 Secondary Research 29
6.3.3 Forecasting 29
6.3.4 Number of Patients Approved to take the Drug 29
6.3.5 Net Penetration of Drug 29
6.3.6 Net Annual Dosing 30
6.3.7 Annual Cost of Therapy 31
6.3.8 Primary Research 31
6.3.9 Expert Panels 31
6.4 Contact Us 31
6.5 Disclaimer 31
6.6 Sources 32


Table 1: Ovarian Cancer, Incidences and Mortality, 20082030 6
Table 2: Ovarian Cancer, Global, Market Size Forecasts ($m), 20092020 8
Table 3: Detailed TNM Classification 13
Table 4: Approval History of Votrient 15
Table 5: Drug Risk Benefit Score of Votrient 16
Table 6: Votrient, Ovarian Cancer, Global, Annual Cost of Therapy ($), 2013 18
Table 7: Votrient, Ovarian Cancer, Global, Sales Forecasts ($m), 20132020 19
Table 8: Votrient, Ovarian Cancer, The US, Sales Forecasts ($m), 20132020 20
Table 9: Votrient, Ovarian Cancer, The UK, Sales Forecasts ($m), 20132020 21
Table 10: Votrient, Ovarian Cancer, France, Sales Forecasts ($m), 20132020 22
Table 11: Votrient, Ovarian Cancer, Germany, Sales Forecasts ($m), 20132020 23
Table 12: Votrient, Ovarian Cancer, Italy, Sales Forecasts ($m), 20132020 24
Table 13: Votrient, Ovarian Cancer, Spain, Sales Forecasts ($m), 20132020 25
Table 14: Votrient, Ovarian Cancer, Japan, Sales Forecasts ($m), 20132020 26


Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010 5
Figure 2: Ovarian Cancer, Global, Market Size Forecasts ($m), 20092020 8
Figure 3: Ovarian Cancer, Worldwide, Incidence (in million), 2008-2030 9
Figure 4: Oncology, Worldwide, Incidence (in million), 2008-2030 10
Figure 5: Ovarian Cancer, Worldwide, Mortality (in million), 2008-2030 10
Figure 6: Broad Classification of Ovarian Cancer 12
Figure 7: Classification of Ovarian Cancer 14
Figure 8: Drug Model Diagram of Votrient 18
Figure 9: Votrient, Ovarian Cancer, Global, Sales Forecasts ($m), 20132020 19
Figure 10: Votrient, Ovarian Cancer, The US, Sales Forecasts ($m), 20132020 20
Figure 11: Votrient, Ovarian Cancer, The UK, Sales Forecasts ($m), 20132020 21
Figure 12: Votrient, Ovarian Cancer, France, Sales Forecasts ($m), 20132020 22
Figure 13: Votrient, Ovarian Cancer, Germany, Sales Forecasts ($m), 20132020 23
Figure 14: Votrient, Ovarian Cancer, Italy, Sales Forecasts ($m), 20132020 24
Figure 15: Votrient, Ovarian Cancer, Spain, Sales Forecasts ($m), 20132020 25
Figure 16: Votrient, Ovarian Cancer, Japan, Sales Forecasts ($m), 20132020 26
Figure 17: Votrient, Ovarian Cancer, Global, Sales Distribution (%), 2020 27
Figure 18: Drug Model Diagram 30
Figure 19: Patients Approved for the Drug 30